Drugs and methods for avoiding inhibition of catechin enzyme activity
By combining acetyl amino acids with catechins, the method prevents protein-induced inhibition, ensuring catechins retain their biological activities for practical applications.
Patent Information
- Application Number
- JP2025077657
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-07
- Publication Date
- 2026-11-19
- Estimated Expiration
- 2045-05-07
AI Technical Summary
Existing methods fail to prevent the loss of catechin biological activity due to protein binding, limiting the practical application of catechins in living organisms.
A mixture of acetyl amino acids, such as acetylisoleucine, acetyltryptophan, and acetylglutamic acid, is combined with catechins and allowed to stand overnight at room temperature to prevent protein-induced inhibition, maintaining catechin activity.
The method allows catechins to maintain their inherent physiological activities by suppressing nonspecific binding to proteins, enabling effective utilization in pharmaceutical, cosmetic, and food compositions.
Smart Images

Figure 2026181890000001 
Figure 2026181890000002
Abstract
Description
TECHNICAL FIELD
[0001] The present invention relates to a method for avoiding the inhibition of enzyme activity by catechins. More specifically, the present invention relates to a substance and a method that can avoid the deactivation of catechins caused by contaminating proteins during an enzyme activity inhibition reaction. BACKGROUND ART
[0002] In recent years, while health consciousness in a broad sense focused on pre-illness states has been advocated, the positioning of lifestyle-related diseases has still not been revised downward, and it can be said that countermeasures against them are growing increasingly important. The booming market of dietary supplements clearly reflects this trend. Among such products, plant polyphenols and the like have seen growing international attention, and numerous international conferences and the like are being actively planned. In particular, among these polyphenols, catechins, which are the main components of green tea, have been the subject of numerous studies and many reported papers due to their diverse biological activities. However, most of these diverse biological activities remain at the stage of experimental results at the laboratory level. Apart from their use as dietary supplements, there is a lack of more specific innovations that aim for practical application using these biological activities as seeds, and it cannot be said that they are actually making significant contributions to social life.
[0003] A re-examination of such catechin research reveals that much of it fails to consider the protein-rich physiological environment that is immediately encountered when catechins are administered to living organisms. While some papers address the loss of catechin's biological activity due to protein, many researchers set aside this attribute of catechin and limit themselves to simple bioactivity measurements at the in vitro or cellular level, which is precisely why the aforementioned innovations have not materialized. On the other hand, some research has attempted to overcome this loss of activity by developing more potent derivatives, but ultimately, this did not prevent the loss of activity due to protein. Considering that tannins, which share the same polyphenol skeleton as catechins, have been used in leather tanning since ancient times due to their strong protein-binding properties (protein coagulation), it is easy to infer that catechins, belonging to the same family, also exhibit strong protein-binding properties and, consequently, a loss of biological activity (for example, Patent Document 1).
[0004] Therefore, there was room for improvement in methods to avoid the loss of catechin's biological activity due to proteins. [Prior art documents] [Patent Documents]
[0005] [Patent Document 1] Patent No. 6792931 [Overview of the Initiative] [Problems that the invention aims to solve]
[0006] This invention provides a substance and method for avoiding inhibition of catechin activity by proteins in the body. [Means for solving the problem]
[0007] (1) A method to avoid inhibition of the physiological activity of catechins by proteins using a mixture of acetyl amino acids and catechins that has been left to stand overnight at room temperature. Here, "a mixture of acetyl amino acids and catechins that has been left to stand overnight at room temperature" refers to a mixture of catechins diluted with physiological saline (saline solution), mixed with N-acetyl amino acids, and left to stand overnight at room temperature. "Avoiding inhibition of the physiological activity of catechins" means "avoiding the inactivation of catechins by interfering proteins during the enzyme activity inhibition reaction of catechins." (2) The method of (1), wherein the acetyl amino acid is one of acetylisoleucine, acetyltryptophan, acetylglutamic acid, and acetylhistidine. (3) An agent that prevents the physiological activity inhibition of catechins by proteins, with acetyl amino acids as the active ingredient. (4) A protein-based agent for preventing the inhibition of the physiological activity of catechins, wherein the acetyl amino acid is one of acetylisoleucine, acetyltryptophan, acetylglutamic acid, and acetylhistidine. (5) A composition comprising an agent for preventing the inhibition of the physiological activity of catechins by the proteins of (3) or (4). (6) The composition of (5), wherein the composition is a pharmaceutical composition, a cosmetic composition, or a food composition. [Effects of the Invention]
[0008] According to the present invention, a method and a drug can be provided that can avoid the inhibition of catechin activity by proteins. [Modes for carrying out the invention]
[0009] Catechins exhibit various physiological activities in in vitro experiments, such as enzyme inhibition and virus inactivation. However, when introduced into living organisms such as the human body, they have been unable to exert sufficient activity due to the influence of existing proteins and other factors.
[0010] We believe that the loss of biological activity due to this protein is the main reason why the in vitro or cellular activity reports do not translate into innovation as predicted. Therefore, we have been exploring ways to avoid protein loading by slightly modifying catechins. This time, we report that several acetylated amino acids have been found to be suitable compounds for this purpose. In other words, in this invention, we have developed a method and an activity inhibition avoidance agent that allows catechins to exert their original activity by avoiding the inhibition of their physiological activity by such endogenous proteins.
[0011] Catechins possess a variety of effects, including, for example, antioxidant, antitumor, anti-cancer, inhibition of plasma cholesterol elevation, inhibition of blood pressure elevation, inhibition of platelet aggregation, inhibition of blood glucose elevation, prevention of dementia, anti-ulcer, anti-inflammatory, antibacterial, antiviral, anticariogenic, anti-dental caries, anti-allergic, detoxification, improvement of gut flora, deodorizing, and lipid metabolism improvement effects. In this specification, these effects are referred to as the "inherent physiological activities of catechins," but this does not limit the scope to these, and also includes the physiological activities of catechins, including derivatives that may be discovered in the future or have already been reported.
[0012] However, when catechins are administered into the body, they have a problem in that their inherent physiological activity is significantly suppressed due to nonspecific binding of proteins and other substances in the body. Therefore, the inventors conducted intensive research and discovered a method and amino acids that can suppress the decrease in physiological activity caused by nonspecific binding of proteins and other substances to catechins, thereby maintaining and exhibiting the original physiological activity of catechins.
[0013] In other words, the present invention provides a catechin-amino acid mixture and a method that suppresses the nonspecific binding of proteins to catechins by coexisting with acetyl amino acids, thereby allowing catechins to exhibit their inherent physiological activity.
[0014] In this invention, "catechins" refers to flavonoids that have flavan-3-ol as their basic skeleton. Molecules included in catechins include, for example, epigallocatechin-3-O-gallate (EGCG), epigallocatechin (EGC), epicatechin-3-O-gallate (ECG), epicatechin (EC), epigallocatechin-3-O(-3-O-methyl)gallate (EGCG3”Me), epigallocatechin-3-O-(4-O-methyl)gallate (EGCG4”Me), theaflavin (TF1), theaflavin-3-gallate (TF2A), theaflavin-3'-gallate (TF2B), theaflavin-3-3·digallate (TF3), theasinensins, thearubigins, etc., but are not limited to these and also include derivatives that have already been reported.
[0015] The inventors discovered that when acetyl amino acids are mixed with catechin and left to stand overnight at room temperature, the inhibition of catechin activity by proteins can sometimes be avoided. Specifically, acetylisoleucine, acetyltryptophan, acetylglutamic acid, or acetylhistidine were mixed with catechin and left overnight at room temperature, after which the inhibition rate of catechin enzyme activity was measured.
[0016] The results are shown in Tables 1 and 2. In Table 2, in the BSA(+) group, acetylisoleucine, acetyltryptophan, acetylglutamic acid, and acetylhistidine all showed values of 23% or less in ratio B;%). In addition, acetyl amino acids showing values in the 40% range were observed, such as acetylglycine at 30.27% and acetyltyrosine at 43.23%. This means that enzyme activity is inhibited (if there is no inhibition at all, enzyme activity will be 100%). In the BSA(-) group on the left of Table 2, the enzyme inhibitory activity (ratio %(B)) without BSA (i.e., in a state without proteins as in a living organism) was 34% or less, indicating that enzyme activity is inhibited in an environment without proteins.
[0017] The "composition" in the present invention may be a food composition, a cosmetic composition, or a pharmaceutical composition. The food composition may be, but is not limited to, a solid food, or a liquid or gel-like food. The pharmaceutical composition may be, for example, but is not limited to, a powder, a tablet, a capsule, a liquid, and the like.
[0018] In the present invention, by allowing an acetylamino acid to interact with such catechins, non-specific binding of proteins to the catechins can be suppressed, and the inherent physiological activity of the catechins can be exerted. The peptide of Patent Document 1 binds to catechins, thereby causing the catechins to inherently possess an inhibitory effect on cell proliferation, but the acetylamino acid used in the present invention is characterized in that it does not inhibit the inherent effects of catechins even when bound to catechins.
[0019] Although the mechanism by which the acetylamino acid of the present invention avoids the activity inhibition of catechins by proteins is unknown, it is presumed that hydrogen bonding, π-π stacking, or the like is probably acting. That is, it can be inferred that the hydrogen bonding of the acetylamino acid to the catechins prevents BSA from forming hydrogen bonds even after BSA is added, making it difficult for BSA to inhibit the activity of the catechins. [Examples]
[0020] Reagents Catechin: Catechin Mixture; Nagara Science. Crystalline powder was dissolved in physiological saline (saline) to 1%. Stored at 4°C, prepared for immediate use. N-Acetylglutamic acid: Tokyo Chemical Industry; Basically, after dissolving to 100 mM in saline, the pH was corrected to neutral with sodium hydroxide. Enzyme: α-Glucosidase; Derived from Oriental Yeast Yeast. Dissolved in 50 mM phosphate buffer (PB) to 50 U / ml and stored at -30°C. Prepared for immediate use. Protein: BSA (bovine serum-derived albumin, Fraction V); Fujifilm. Dissolve to 5% in saline, store at 4°C as stock solution, prepare as needed before use. Enzyme substrate: p-nitrophenyl-α-d-glucopyranoside (PNGP); Nacalai Tesque. Adjust to 20 mM with PBS, store at 4°C, prepare as needed before use. Tris(hydroxymethyl)aminomethane (Tris): Fujifilm; adjust to 1 M with Milli-Q water, store at 4°C, prepare as needed before use.
[0021] List of acetylamino acids examined by the above method: N-Acetyl-L-alanine, N-Acetyl-L-leucine, N-Acetyl-L-methionine, N-Acetyl-L-valine, N-Acetyl-L-phenylalanine, N-Acetyl-L-tryptophan, N-Acetyl-L-tyrosine, O-Acetyl-L-serine, N-Acetyl-L-, Acetyl-glutamic acid, N-Acetyl-L-histidine, N α -Acetyl-L-lysine, N ε -Acetyl-L-lysine, N-Acetyl-L-guanidine, all above: Tokyo Chemical Industry N-Acetyl-L-cysteine: Kishida Chemical N-Acetyl-L-asparagine, N-Acetyl-L-aspartic acid, N-Acetyl-L-proline: SIGMA ALDRICH N-Acetyl-L-isoleucine, N-Acetyl-L-glutamine: Fluorochem Ltd. N-Acetyl-L-serine: Cembi-Blocks N α -Acetyl-L-arginine: Matrix Scientific N-Acetyl-L-glycine: Sigma Aldrich Microplate: Corning; flat-bottom 96-well microplate.
[0022] Preparation of modified catechin: Dilute the catechin stock solution to 100 μL with saline, mix with an equal volume of N-acetylamino acid diluted to 21.8 mM, allow the mixture to react overnight at room temperature (25±2°C), and store the resulting modified catechin at 4°C.
[0023] Enzyme reaction: 30 μl of enzyme dilution, adjusted to 0.1 U / ml with 50 mM PB, was added to each well containing 40 μl of the preceding reagent (specifically, the reaction solution of catechin and protein), and the reaction was allowed to proceed at room temperature for 2 hours. Meanwhile, 50 μl of PNGp diluted 40-fold with 50 mM PB was prepared and added to the reaction mixture after the protein loading reaction was completed, and the enzymatic reaction was carried out at 37°C. After 30 minutes of incubation, 100 μl of 1 M Tris stock solution was added to each well as an enzyme reaction stopper to terminate the reaction. The absorbance at 400 nm of the plate after the reaction was measured using a PerkinElmer Multimode Plate Reader to detect the yellow color of picric acid released by the enzyme.
[0024] result Experiments on the loss of enzyme activity inhibition by protein loading of catechins and modified catechins in enzymatic reactions: 5% BSA stock solution was diluted with saline in five stages to 0.3, 0.2, 0.1, 0.05, and 0.03 mg / ml, and 20 μl of each was injected into two wells of a designated microplate. 20 μl of 100 μg / ml catechin and modified catechin dilution was then added. The mixture was thoroughly mixed with a mixer and incubated at room temperature for 2 hours. After the reaction, 30 μl of enzyme dilution adjusted to 0.1 U / ml with 50 mM PB was added to each well, and the reaction was incubated at room temperature for another 2 hours. Enzyme activity was measured using the method described above, and the enzyme activity inhibition rate and its recovery rate (which should be considered as the protein evasion rate of modified catechin) were calculated using the calculation method described later.
[0025] [Table 1]
[0026] Table 1 shows the measured values of the reaction mixture, in which acetylglutamic acid was added to catechin as a modified catechin. Average OD (= absorbance at 400 nm) x 10⁻¹⁰ of each sample in 2 wells. 4)- The values shown are those after subtracting the blank 300 of the plate. It can be seen that as the concentration of added BSA increases, enzyme activity inhibition by catechin (+) is avoided (enzyme activity increases). The "difference" between the enzyme activity of catechin alone and the enzyme activity of modified catechin at 0.05 mg / ml of BSA (74.6 - 4.77 = 69.83) is in good agreement with the acetylglutamic acid value in "Table 2" of the screening experiment.
[0027] Table 2 shows the results of a screening of acetylamino acids that can evade protein-induced inhibition of catechin enzyme activity using a mixture of acetylamino acids and catechins. Those with a high rate of protein load evasion are indicated with ++ in the effectiveness column. In the BSA(+) group, where BSA was added, acetylisoleucine, acetyltryptophan, acetylglutamic acid, and acetylhistidine all showed values of 23% or less in ratio B;%). In addition, acetylamino acids showing values in the 40% range were observed, such as acetylglycine at 30.27% and acetyltyrosine at 43.23%. This means that enzyme activity is inhibited (if there is no inhibition at all, enzyme activity will be 100%). In the BSA(-) group on the left of Table 2, the enzyme inhibitory activity (ratio %(B)) without BSA (i.e., in a state without protein, as in a living organism) was 34% or less, indicating that enzyme activity is inhibited by catechin in an environment without protein.
[0028] [Table 2] [Industrial applicability]
[0029] This invention can be used in the medical industry, the health food industry, and other fields.
Claims
1. A method to avoid inhibition of the physiological activity of catechins by proteins, using a mixture of acetyl amino acids and catechins that has been left to stand overnight at room temperature.
2. The method according to claim 1, wherein the acetyl amino acid is any one of acetylisoleucine, acetyltryptophan, acetylglutamic acid, and acetylhistidine.
3. An agent that prevents the physiological activity inhibition of catechins by proteins, with acetyl amino acids as the active ingredient.
4. The protein-based agent for preventing inhibition of the physiological activity of catechins according to claim 3, wherein the acetyl amino acid is one of acetylisoleucine, acetyltryptophan, acetylglutamic acid, and acetylhistidine.
5. A composition comprising an agent for preventing the inhibition of the physiological activity of catechins by the protein of claim 3 or 4.
6. The composition according to claim 5, wherein the composition is a pharmaceutical composition, a cosmetic composition, or a food composition.
Citation Information
Patent Citations
Strategy to avoid catechins binding to unspecified proteins and preparation of pilot samples
JP6792931B1
